Volume 61, Issue 5, Pages (November 2014)

Slides:



Advertisements
Similar presentations
EASL Clinical Practice Guidelines: Vascular diseases of the liver Journal of Hepatology Volume 64, Issue 1, Pages (January 2016) DOI: /j.jhep
Advertisements

Depression, anemia and health-related quality of life in chronic hepatitis C Amy A. Dan, Lisa M. Martin, Cathy Crone, Janus P. Ong, Denise W. Farmer, Thomas.
Omega 3 – Omega 6: What is right for the liver? Ashraf Mohammad El-Badry, Rolf Graf, Pierre-Alain Clavien Journal of Hepatology Volume 47, Issue 5, Pages.
Volume 63, Issue 1, Pages (July 2015)
Volume 46, Issue 3, Pages (March 2007)
The impact of hepatitis E in the liver transplant setting
Kirsten Boonstra, Ulrich Beuers, Cyriel Y. Ponsioen 
Inflammasomes in liver diseases
Volume 67, Issue 5, Pages (November 2017)
Volume 50, Issue 4, Pages (April 2009)
Sebelipase alfa Protein chemical formula : C1968H2945N507O551S15
Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults: A systematic review  Christian Thoma, Christopher P. Day, Michael.
MELD score is a better prognostic model than Child-Turcotte-Pugh score or Discriminant Function score in patients with alcoholic hepatitis  Wichit Srikureja,
MRI and MRE for non-invasive quantitative assessment of hepatic steatosis and fibrosis in NAFLD and NASH: Clinical trials to clinical practice  Parambir.
Halis Simsek, Ali Shorbagi, Yasemin Balaban, Gonca Tatar 
The impact of hepatitis E in the liver transplant setting
Matthew T. Kitson, Stuart K. Roberts  Journal of Hepatology 
Volume 44, Issue 4, Pages (April 2006)
Volume 148, Issue 4, Pages e8 (April 2015)
KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update
Immigration and viral hepatitis
Sebelipase alfa improves atherogenic biomarkers in adults and children with lysosomal acid lipase deficiency  Don P. Wilson, MD, FNLA, Mark Friedman,
Living donor liver transplantation: is the hype over?
Marina Cuchel, Dirk J. Blom, Maurizio R. Averna 
Lysosomal acid lipase deficiency: A hidden disease among cohorts of familial hypercholesterolemia?  Joana Rita Chora, MSc, Ana Catarina Alves, PhD, Ana.
Hepatitis C core protein – The “core” of immune deception?
Charles J. Glueck, MD, Alan Brown, MD, Anne C. Goldberg, MD, James M
Statin use and the risk of hepatocellular carcinoma in patients at high risk: A nationwide nested case-control study  Gyuri Kim, Suk-Yong Jang, Chung.
Serum markers of hepatic fibrogenesis in cystic fibrosis liver disease
Volume 61, Issue 5, Pages (November 2014)
Volume 59, Issue 3, Pages (September 2013)
Volume 61, Issue 1, Pages S69-S78 (November 2014)
Volume 62, Issue 3, Pages (March 2015)
Acute hepatitis C: Current status and remaining challenges
Volume 155, Issue 5, Pages e6 (November 2018)
Darius Moradpour, Arash Grakoui, Michael P. Manns 
Autophagy in the liver Journal of Hepatology
Behzad Hajarizadeh, Jason Grebely, Gregory J. Dore 
EASL Clinical Practice Guidelines: Wilson’s disease
Laboratory parameter profiles among patients with cystic fibrosis
Volume 61, Issue 1, Pages S45-S57 (November 2014)
Volume 69, Issue 6, Pages (December 2018)
Volume 70, Issue 1, Pages (January 2019)
Volume 65, Issue 2, Pages (August 2016)
Volume 57, Issue 5, Pages (November 2012)
Efficacy and Safety of Sebelipase Alfa in Children and Adults with Lysosomal Acid Lipase Deficiency: Results of a Phase 3 Trial†  Sandra Rojas-Caro, Barbara.
Histologic Changes in Liver Tissue From Patients With Chronic Hepatitis B and Minimal Increases in Levels of Alanine Aminotransferase: A Meta-analysis.
Volume 50, Issue 4, Pages (April 2009)
Volume 70, Issue 3, Pages (March 2019)
Non-invasive diagnosis and biomarkers in alcohol-related liver disease
Antiviral therapy for chronic hepatitis B: Challenges in Hong Kong
Volume 67, Issue 5, Pages (November 2017)
Influence of low-glucose peritoneal dialysis on serum lipids and apolipoproteins in the IMPENDIA/EDEN trials  Allan D. Sniderman, MD, James A. Sloand,
Volume 50, Issue 3, Pages (March 2009)
Immigration and viral hepatitis
Volume 64, Issue 6, Pages (June 2016)
Suna Yapali, MD, Anna S. Lok, MD, FRCP 
Volume 63, Issue 1, Pages (July 2015)
Close monitoring of serum HBV DNA levels and liver enzymes levels is most useful in the management of patients with occult HBV infection  Isabelle Chemin,
Rhanderson Cardoso, MD, Roger S
Chronic hepatitis B in children and adolescents
Hepatorenal syndrome, MELD score and liver transplantation: An evolving issue with relevant implications for clinical practice  Paolo Angeli, Pere Gines 
Volume 62, Issue 3, Pages (March 2015)
Volume 54, Issue 2, Pages (February 2011)
Liver transplantation in children
Pathogenesis of cholestatic hepatitis C
Chimeric mouse model of hepatitis B virus infection
U.P. Neumann, M. Biermer, D. Eurich, P. Neuhaus, T. Berg 
Long-term clinical results of microsomal triglyceride transfer protein inhibitor use in a patient with homozygous familial hypercholesterolemia  Anna.
Fondaparinux (Arixtra∗) hepatotoxicity in a 6 year-old child
Presentation transcript:

Volume 61, Issue 5, Pages 1135-1142 (November 2014) Sebelipase alfa over 52weeks reduces serum transaminases, liver volume and improves serum lipids in patients with lysosomal acid lipase deficiency  Vassili Valayannopoulos, Vera Malinova, Tomas Honzík, Manisha Balwani, Catherine Breen, Patrick B. Deegan, Gregory M. Enns, Simon A. Jones, John P. Kane, Eveline O. Stock, Radhika Tripuraneni, Stephen Eckert, Eugene Schneider, Gavin Hamilton, Michael S. Middleton, Claude Sirlin, Bruce Kessler, Christopher Bourdon, Simeon A. Boyadjiev, Reena Sharma, Chris Twelves, Chester B. Whitley, Anthony G. Quinn  Journal of Hepatology  Volume 61, Issue 5, Pages 1135-1142 (November 2014) DOI: 10.1016/j.jhep.2014.06.022 Copyright © 2014 European Association for the Study of the Liver Terms and Conditions

Fig. 1 Flow chart diagram of the LAL-CL01 and LAL-CL04 study design. Subjects (18–65yr) were required to have documented LAL deficiency, hepatomegaly and/or transaminases >1.5×ULN, and may be on a lipid-lowering agents (stable dose for ⩾4weeks). LAL, Lysosomal acid lipase; qw, once weekly; qow, once every other week. Journal of Hepatology 2014 61, 1135-1142DOI: (10.1016/j.jhep.2014.06.022) Copyright © 2014 European Association for the Study of the Liver Terms and Conditions

Fig. 2 Mean hepatic transaminases (U/L) in LAL-CL04 study (n=8). All one-week-post-infusion laboratory data are presented one week after the week 24 visit. ALT, alanine transaminase; AST, aspartate aminotransferase; qw, once weekly; qow, once every other week. Journal of Hepatology 2014 61, 1135-1142DOI: (10.1016/j.jhep.2014.06.022) Copyright © 2014 European Association for the Study of the Liver Terms and Conditions

Fig. 3 Mean percent change from LAL-CL01 baseline for serum lipids in LAL-CL04 study (n=8). All one-week-post-infusion laboratory data are presented one week after the week 24 visit. HDL, high-density lipoprotein-cholesterol; LDL, low density lipoprotein-cholesterol; Trig, triglycerides. Journal of Hepatology 2014 61, 1135-1142DOI: (10.1016/j.jhep.2014.06.022) Copyright © 2014 European Association for the Study of the Liver Terms and Conditions

Fig. 4 Absolute LDL values over time (n=8). Journal of Hepatology 2014 61, 1135-1142DOI: (10.1016/j.jhep.2014.06.022) Copyright © 2014 European Association for the Study of the Liver Terms and Conditions

Fig. 5 Change in liver volume and hepatic PDFF in LAL-CL04. ∗One patient did not have a LAL-CL04 baseline assessment, thus, numbers are decreased by one, relative to liver volume. Journal of Hepatology 2014 61, 1135-1142DOI: (10.1016/j.jhep.2014.06.022) Copyright © 2014 European Association for the Study of the Liver Terms and Conditions